Carbonic anhydrase inhibitors: Synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties
摘要:
A series of 4 and 5 nitro-1,3-dioxoisoindolin-2-yl benzenesulfonamide derivatives (compounds 1-8) was synthesized by reaction of benzenesulfonamide derivatives with 4 and 3-nitrophthalic anhydrides. These new sulfonamides were investigated as inhibitors of the zinc metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) and more specifically against the human (h) cytosolic isoforms hCA I and II and the transmembrane, tumor-associated hCA IX and XII. Most of the novel compounds were medium potency-weak hCA I inhibitors (K(i)s in the range of 295-10,000 nM), but were more effective hCA II inhibitors (K(i)s of 1.7-887 nM). The tumor-associated hCA IX was also inhibited, with K(i)s in the micromolar range, whereas against hCA XII the inhibition constants were in the range of 90-3746 nM. The structure-activity relationship (SAR) with this series of sulfonamides is straightforward, with the main features leading to good activity for each isoforms being established. The high sequence hCA alignment homology and molecular docking studies was performed in order to rationalize the activities reported and binding mode to different hCA as inhibitors. (C) 2014 Elsevier Ltd. All rights reserved.
Carbonic anhydrase inhibitors: Synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties
作者:Kalyan K. Sethi、Saurabh M. Verma、Muhammet Tanç、Gaultier Purper、Gaetan Calafato、Fabrizio Carta、Claudiu T. Supuran
DOI:10.1016/j.bmc.2014.01.031
日期:2014.3
A series of 4 and 5 nitro-1,3-dioxoisoindolin-2-yl benzenesulfonamide derivatives (compounds 1-8) was synthesized by reaction of benzenesulfonamide derivatives with 4 and 3-nitrophthalic anhydrides. These new sulfonamides were investigated as inhibitors of the zinc metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) and more specifically against the human (h) cytosolic isoforms hCA I and II and the transmembrane, tumor-associated hCA IX and XII. Most of the novel compounds were medium potency-weak hCA I inhibitors (K(i)s in the range of 295-10,000 nM), but were more effective hCA II inhibitors (K(i)s of 1.7-887 nM). The tumor-associated hCA IX was also inhibited, with K(i)s in the micromolar range, whereas against hCA XII the inhibition constants were in the range of 90-3746 nM. The structure-activity relationship (SAR) with this series of sulfonamides is straightforward, with the main features leading to good activity for each isoforms being established. The high sequence hCA alignment homology and molecular docking studies was performed in order to rationalize the activities reported and binding mode to different hCA as inhibitors. (C) 2014 Elsevier Ltd. All rights reserved.